Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045708 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT00045708: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00045708 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 57 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00045708, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. This phase I/II trial is studying the side effects and best dose of ixabepilone and how well it works in treating patients with recurrent glioma.
Interventions
- OTHER pharmacological study
- DRUG ixabepilone
- DRUG Anticonvulsant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2002-10 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045708
The ClinicalTrials.gov registry entry for NCT00045708 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which pharmacological study is the first listed.
NCT00045708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00045708 about?
NCT00045708 is a clinical study titled "A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas". Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. This phase I/II trial is studying the side effects and best dose of ixabepilone and how well it works in treating patients with recurrent glioma.
What is the current status of trial NCT00045708?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2002-10. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00045708?
The interventions under investigation include: pharmacological study (OTHER), ixabepilone (DRUG), Anticonvulsant (DRUG).
Who is sponsoring clinical trial NCT00045708?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.